Haemonetics Corporation EPS (Earnings per Share) 2009–2026
Haemonetics Corporation reported $2.05 of earnings per share for fiscal 2026. That was 38.1% lower than fiscal 2025. Compared with fiscal 2021, the change was +32.3%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2026 | $2.05 | -38.1% |
| FY 2025 | $3.31 | +44.5% |
| FY 2024 | $2.29 | +2.2% |
| FY 2023 | $2.24 | +166.7% |
| FY 2022 | $0.84 | -45.8% |
| FY 2021 | $1.55 | +4.7% |
| FY 2020 | $1.48 | +42.3% |
| FY 2019 | $1.04 | +22.4% |
| FY 2018 | $0.85 | +266.7% |
| FY 2017 | $-0.51 | +53.2% |
| FY 2016 | $-1.09 | -440.6% |
| FY 2015 | $0.32 | -52.2% |
| FY 2014 | $0.67 | -9.5% |
| FY 2013 | $0.74 | -43.1% |
| FY 2012 | $1.30 | -16.7% |
| FY 2011 | $1.56 | +39.3% |
| FY 2010 | $1.12 | -1.3% |
| FY 2009 | $1.14 | — |
Source: Haemonetics Corporation SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HAE 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Haemonetics Corporation reported $2.05 of earnings per share for fiscal 2026. That was 38.1% lower than fiscal 2025. Compared with fiscal 2021, the change was +32.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Haemonetics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHaemonetics Corporation — frequently asked questions
What is Haemonetics Corporation's earnings per share?
Haemonetics Corporation (HAE) reported earnings per share of $2.05 for fiscal year 2026, per its SEC filings.
How has Haemonetics Corporation's earnings per share changed over time?
Between fiscal 2009 and 2026, HAE's earnings per share grew at roughly 3.5% per year (compound annual rate), from $1.14 to $2.05.
Where does this data come from?
Figures are computed from Haemonetics Corporation's official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.